RT Journal Article
T1 Cognitive Profile of Zonisamide and Valproic Acid in the Treatment of Idiopathic Generalized Epilepsy: A Comparative Observational Study
A1 Ramirez-Garcia, Teresa
A1 Serrano-Castro, Pedro J.
A1 Alonso-Morillejo, Enrique
A1 Perea-Justicia, Patricia
A1 Iglesias-Espinosa, Mar
A1 Parron-Carreno, Tesifon
K1 Cognitive profile
K1 Idiopathic generalized epilepsy
K1 Neuropsychology
K1 Valproic acid
K1 Zonisamide
K1 Antiepileptic drugs
K1 Focal epilepsy
K1 Efficacy
K1 Monotherapy
K1 Tolerability
K1 Topiramate
K1 Disorders
K1 Seizures
K1 Therapy
AB Introduction: Calls for an alternative to valproic acid (VPA) as drug of choice for idiopathic generalized epilepsies (IGEs) have intensified since the recent International League Against Epilepsy recommendation that the drug should not be administered to women of childbearing age. Zonisamide (ZNS), a third-generation antiepileptic drug, has proven effective in generalized seizures and could be considered an alternative to VPA in this population.Objectives: The present study was designed to examine possible differences in cognitive profile between ZNS and VPA as monotherapy in patients with IGE in real-life settings.Methods: We conducted a comparative, descriptive, observational, retrospective cohort study in two groups of patients diagnosed with IGE treated with ZNS C200 mg/day or VPA C1000 mg/day as stable monotherapy for at least the previous 6 months. We used specific neuropsychological tests for short-and long-term mnemonic functions, working memory, visuospatial speed, attention and processing speed, verbal fluency, executive functions, visual perception, abstraction, anxiety, depression, and apathy.Results: We included 16 patients in the study: eight in the VPA and eight in the ZNS group. Significantly superior mean scores were obtained by the VPA group in working memory (Forward Digits test) and by the ZNS group in execution time for the Rey-Osterrieth complex figure test. No statistically significant differences were found between the groups in the remaining tests.Conclusion: Zonisamide as monotherapy has a similar cognitive profile to that of VPA in patients with IGE. The final treatment selection setting should be individualized. ZNS may be a reasonable alternative to VPA in some cases in this population.
PB Springer london ltd
SN 2193-8253
YR 2016
FD 2016-06-01
LK http://hdl.handle.net/10668/18664
UL http://hdl.handle.net/10668/18664
LA en
DS RISalud
RD Apr 7, 2025